Gracell Biotechnologies
Suzhou
About Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $285.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Aug 2023)
- Ticker: nasdaq:GRCL
- Website: gracellbio.com
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/gracell-biotechnologies-196715 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.